Kimia Biosciences Ltd
NSE: BSE: 530313
₹33.69
(0%)
Wed, 04 Mar 2026, 08:46 pm
Market Cap1.59B
PE Ratio17.61
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KKimia Biosciences Analysis
dividend
- Unable to evaluate Kimia Biosciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Kimia Biosciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Kimia Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Kimia Biosciences is profitable, therefore cash runway is not a concern.
- Kimia Biosciences is profitable, therefore cash runway is not a concern.
- Debt is covered by short term assets, assets are 1.8x debt.
- Kimia Biosciences's cash and other short term assets cover its long term commitments.
- Operating cash flow is negative therefore debt is not well covered.
- The level of debt compared to net worth has increased over the past 5 years (100.2% vs 230.4% today).
- Interest payments on debt are not well covered by earnings (EBIT is 2.3x annual interest expense, ideally 3x coverage).
- Kimia Biosciences's level of debt (230.4%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Kimia Biosciences board of directors is about average.
- Sameer's remuneration is about average for companies of similar size in India.
- The tenure for the Kimia Biosciences management team is about average.
misc
- Kimia Biosciences is not covered by any analysts.
past
- Kimia Biosciences has delivered over 20% year on year earnings growth in the past 5 years.
- Kimia Biosciences has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
- Kimia Biosciences's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- Kimia Biosciences used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Kimia Biosciences has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Kimia Biosciences's 1-year earnings growth is negative, it can't be compared to the IN Pharmaceuticals industry average.
value
- BSE:530313 is up 8.7% outperforming the Pharmaceuticals industry which returned 6.2% over the past month.
- BSE:530313 is up 8.7% along with the India market (9%) over the past month.
- Kimia Biosciences is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Kimia Biosciences is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- Kimia Biosciences is overvalued based on earnings compared to the India market.
- 530313 underperformed the Pharmaceuticals industry which returned 24.6% over the past year.
- 530313 underperformed the Market in India which returned -14.8% over the past year.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800